Estudios sobre violencia en la educación. Enfoques, textos y contextos

El concepto de la violencia ha estado sobre la palestra desde el principio de nuestras sociedades. No obstante, en la práctica sus facetas son múltiples y en diversos ámbitos, lo que ha dado lugar a especulaciones acerca de los medios y los fines. Esto mismo incita a reflexionar en lo axiológico, pues la violencia alberga en sí un elemento adicional de arbitrariedad y, por lo tanto, se relaciona con aspectos fundamentales del derecho o los derechos humanos. En los ámbitos educativos han aparecido nuevas formas de violencia personal, que se reflejan en el bullying y el mobbing. En el ámbito universitario, existe un malestar que no se palía con estímulos o clientelismos y que se refiere a un tipo de violencia particular soterrada por las políticas públicas y el intervencionismo del Estado, los cuales han provocado tensiones entre las comunidades académicas; éstas tienen que ver con la defensa de los principios de libertad y autonomía de cátedra e investigación. En algunos casos, dichas voces han formulado críticas a los programas impuestos, ya que éstos se establecen sin reflexionar en los costos sociales que provocan en el trabajo académico y científico. De esas formas de violencia se quiere dar cuenta en esta obra, la cual fue desarrollada por la Red de Cuerpos Académicos en Política, Educación y Universidad

Adelante / Endavant

Séptimo desafío por la erradicación de la violencia contra las mujeres del Institut Universitari d’Estudis Feministes i de Gènere "Purificación Escribano" de la Universitat Jaume

Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trialResearch in context

Summary: Background: Anti-COVID-19 hyperimmune immunoglobulin (hIG) can provide standardized and controlled antibody content. Data from controlled clinical trials using hIG for the prevention or treatment of COVID-19 outpatients have not been reported. We assessed the safety and efficacy of subcutaneous anti-COVID-19 hyperimmune immunoglobulin 20% (C19-IG20%) compared to placebo in preventing development of symptomatic COVID-19 in asymptomatic individuals with SARS-CoV-2 infection. Methods: We did a multicentre, randomized, double-blind, placebo-controlled trial, in asymptomatic unvaccinated adults (≥18 years of age) with confirmed SARS-CoV-2 infection within 5 days between April 28 and December 27, 2021. Participants were randomly assigned (1:1:1) to receive a blinded subcutaneous infusion of 10 mL with 1 g or 2 g of C19-IG20%, or an equivalent volume of saline as placebo. The primary endpoint was the proportion of participants who remained asymptomatic through day 14 after infusion. Secondary endpoints included the proportion of individuals who required oxygen supplementation, any medically attended visit, hospitalisation, or ICU, and viral load reduction and viral clearance in nasopharyngeal swabs. Safety was assessed as the proportion of patients with adverse events. The trial was terminated early due to a lack of potential benefit in the target population in a planned interim analysis conducted in December 2021. ClinicalTrials.gov registry: NCT04847141. Findings: 461 individuals (mean age 39.6 years [SD 12.8]) were randomized and received the intervention within a mean of 3.1 (SD 1.27) days from a positive SARS-CoV-2 test. In the prespecified modified intention-to-treat analysis that included only participants who received a subcutaneous infusion, the primary outcome occurred in 59.9% (91/152) of participants receiving 1 g C19-IG20%, 64.7% (99/153) receiving 2 g, and 63.5% (99/156) receiving placebo (difference in proportions 1 g C19-IG20% vs. placebo, −3.6%; 95% CI -14.6% to 7.3%, p = 0.53; 2 g C19-IG20% vs placebo, 1.1%; −9.6% to 11.9%, p = 0.85). None of the secondary clinical efficacy endpoints or virological endpoints were significantly different between study groups. Adverse event rate was similar between groups, and no severe or life-threatening adverse events related to investigational product infusion were reported. Interpretation: Our findings suggested that administration of subcutaneous human hyperimmune immunoglobulin C19-IG20% to asymptomatic individuals with SARS-CoV-2 infection was safe but did not prevent development of symptomatic COVID-19. Funding: Grifols